Disseminated Intravascular Coagulation (DIC)
Conditions
Brief summary
To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using multi-center, non-comparative, open-label method in patients diagnosed as disseminated intravascular coagulation (DIC) by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare.
Interventions
DRUGKW-3357
Intravenous infusion once a day
Sponsors
Kyowa Kirin Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed or suspected as DIC by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare * Antithrombin activity \<= 70% * Written informed consent from patient or guardian
Exclusion criteria
* Anamnesis or complication of serious drug allergy * Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis * Pregnant, nursing, or possibly pregnant woman * Possibility for the promotion of bleeding by concomitant use of heparin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | up to 6 days (or discontinuation) | Number of patients with adverse events |
| DIC resolution | 6 days (or discontinuation) | Resolution from DIC by the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DIC score | Screening, 2, 3, 4, 5, 6 days (or discontinuation) | Based on the diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare |
| Mortality | 28 days | — |
| Plasma antithrombin activity | Screening, 2, 3, 4, 5, 6 days (or discontinuation) | — |
Countries
Japan
Outcome results
None listed